3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Meet the Veristat team at ASCO, May 31st to June 4th in Chicago
The Science-First CRO™ and Consultancy Ready to Advance Your Revolutionary Therapy's Development, Approval, and Commercialization.
If you are transitioning your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or are looking to recruit patients quickly to get your early phase trials running, or just need medical writing, biostatistical,or pharmacovigilance support for your programs – Veristat can help.
For 30 years, Veristat has helped pharmaceutical and biotech companies accelerate their clinical trials and commercialize their therapies by delivering Science-First solutions across the development lifecycle.
Oncology/Hematology Experience in the Past 5 Years
- +400 Clinical Trials & Consulting Projects
- +30 Marketing Applications (NDAs, BLAs, MAAs) Prepared
- 90% of global operations team members have oncology/hematology experience
We provide impactful solutions on a full-service or functional service basis, integrating strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel therapies.
Our expertise encompasses traditional cancer treatments, devices/diagnostics, and specialized therapies, including vaccines, gene and cell therapies, and immunotherapies.
Don't miss this opportunity to connect with us at the Conference and learn more about how Veristat is advancing the development of new oncology therapies.
The Science-First CRO.™
Schedule A Meeting
Veristat team members, AJ Mills, Vice President, Global Commercial, and Gabriela Rosu, Senior Director, Global Medical Affairs, will be at the venue, ready to listen to your needs and share Veristat’s expertise. Discover what makes Veristat a distinguished name in the clinical research industry.
Arrange a meeting by completing the form on the right side of this page.
Conference Details
Website: ASCO 2024
Schedule A Meeting
Meet with us at ASCO 2024 by filling out the form below.
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...